LON:ROQ Roquefort Therapeutics (ROQ) Share Price, News & Analysis GBX 1.43 -0.12 (-7.74%) As of 05:22 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Roquefort Therapeutics Stock (LON:ROQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Roquefort Therapeutics alerts:Sign Up Key Stats Today's Range 1.43▼ 1.5550-Day Range 1.33▼ 252-Week Range 1.08▼ 6.78Volume489,593 shsAverage Volume2.12 million shsMarket Capitalization£1.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Read More Receive ROQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ROQ Stock News HeadlinesStephen Paul West Purchases 2,400,000 Shares of Roquefort Therapeutics plc (LON:ROQ) StockJuly 8 at 2:19 AM | insidertrades.comInsider Buying: Roquefort Therapeutics plc (LON:ROQ) Insider Buys 72,507 Shares of StockJuly 1, 2025 | insidertrades.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 9 at 2:00 AM | Crypto 101 Media (Ad)Insider Buying: Roquefort Therapeutics plc (LON:ROQ) Insider Acquires 72,507 Shares of StockJuly 2, 2025 | americanbankingnews.comRoquefort Thera Share Chat (ROQ)June 21, 2025 | lse.co.ukSMALL-CAP WINNERS & LOSERS: Roquefort jumps on Oncogeni dealMarch 10, 2025 | lse.co.ukRoquefort Therapeutics CEO resigns, agrees terms for Oncogeni disposalMarch 10, 2025 | lse.co.ukSMALL CAP IDEA: Roquefort finds pharma diamonds in the roughFebruary 10, 2025 | msn.comSee More Headlines ROQ Stock Analysis - Frequently Asked Questions How have ROQ shares performed this year? Roquefort Therapeutics' stock was trading at GBX 4.10 at the beginning of the year. Since then, ROQ shares have decreased by 65.1% and is now trading at GBX 1.43. How were Roquefort Therapeutics' earnings last quarter? Roquefort Therapeutics plc (LON:ROQ) issued its quarterly earnings results on Wednesday, April, 30th. The company reported ($0.75) earnings per share for the quarter. Roquefort Therapeutics had a negative trailing twelve-month return on equity of 29.57% and a negative net margin of 57,057.07%. How do I buy shares of Roquefort Therapeutics? Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Roquefort Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roquefort Therapeutics investors own include Vislink Technologies (XGTI), AutoZone (AZO), Intel (INTC), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), TJX Companies (TJX) and Abacus Health Products (ABAHF). Company Calendar Last Earnings4/30/2025Today7/09/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ROQ CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.52 million Net Margins-57,057.07% Pretax MarginN/A Return on Equity-29.57% Return on Assets-15.86% Debt Debt-to-Equity Ratio12.37 Current Ratio0.79 Quick Ratio3.07 Sales & Book Value Annual Sales£2.66 thousand Price / Sales683.51 Cash FlowGBX 0.96 per share Price / Cash Flow1.49 Book ValueGBX 3.82 per share Price / Book0.37Miscellaneous Outstanding Shares127,254,864Free FloatN/AMarket Cap£1.82 million OptionableNot Optionable Beta0.05 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (LON:ROQ) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.